Herbalife Ltd. Common Shares (HLF)
Stock · NYSE · Health Care
$14.59as of 10/16/2026
Price chart
Active signals
HLF Signal Track Record
How signals performed across all stocks →What HLF's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | -2.5% | 48% | September 18, 2026 |
| Bollinger Band Breakdown | 23 | -3.0% | 39% | August 31, 2026 |
| Bollinger Band Breakout | 22 | -1.2% | 45% | October 9, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -11.2% | 9% | June 30, 2026 |
| Any 20-session window (baseline) | -1.8% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HLF
Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers weight management products, including meal replacement, protein shakes, drink mixes, weight loss supplements, healthy snacks, and metabolism boosting teas; targeted nutrition products comprising functional bev…
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- Employees
- 8,500
- Website
- www.herbalife.com/
Fundamentals
- 1-day range
- $14.27$14.71
- Market cap
- $1.19B
- P/E (trailing)
- 9.24
- P/E (forward)
- 4.73
- EPS (trailing)
- $1.55
- Dividend yield
- —
- Beta
- 0.75
- Avg. volume
- 1.54M
- Ex-dividend date
- February 28, 2014
- Dividend pay date
- March 18, 2014
How Herbalife Ltd. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Herbalife Ltd. Common Shares Competitors
Chosen by industry and closest market cap.
- HLFHerbalife Ltd. Common Shares$14.6▲ 0.21%Market cap $1.19BP/E 9.24$7.56$20.4
- NUSNu Skin Enterprises Inc. Common Stock$5.14▼ 1.34%Market cap $251.98MP/E 4.30$4.45$11.67
- ZSTKZeroStack Corp. Common Stock$4▼ 5.21%Market cap $30.78MP/E —$1.32$20.45
- HKPDCellyan Biotechnology Co. Ltd Class A Ordinary Shares$0.11▲ 0.00%Market cap $16.93MP/E —$0.095$1.72
- COSMCosmos Health Inc. Common Stock$0.331▼ 1.49%Market cap $13.72MP/E —$0.1616$1.26
- MEDSDataMeds AI Inc. Common Stock$2.63▼ 7.72%Market cap $7.52MP/E —$0.8225$12.31
- CAHCardinal Health Inc. Common Stock$254.06▲ 0.14%Market cap $55.66BP/E 33.97$152.46$258.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HLF Herbalife Ltd. Common Shares | $1.19B | 9.24 | $14.6 | ▲ 0.21% | $7.56$20.4 |
| NUS Nu Skin Enterprises Inc. Common Stock | $251.98M | 4.30 | $5.14 | ▼ 1.34% | $4.45$11.67 |
| ZSTK ZeroStack Corp. Common Stock | $30.78M | — | $4 | ▼ 5.21% | $1.32$20.45 |
| HKPD Cellyan Biotechnology Co. Ltd Class A Ordinary Shares | $16.93M | — | $0.11 | ▲ 0.00% | $0.095$1.72 |
| COSM Cosmos Health Inc. Common Stock | $13.72M | — | $0.331 | ▼ 1.49% | $0.1616$1.26 |
| MEDS DataMeds AI Inc. Common Stock | $7.52M | — | $2.63 | ▼ 7.72% | $0.8225$12.31 |
| CAH Cardinal Health Inc. Common Stock | $55.66B | 33.97 | $254.06 | ▲ 0.14% | $152.46$258.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Top 3 Risk Off Stocks You May Want To Dump In Q4benzinga · 10/13/2026
- 3 Reasons to Avoid HLF and 1 Stock to Buy InsteadYahoo · 10/8/2026
- Why Is Everyone Ignoring Celsius Stock's High Cash Yield?Yahoo · 10/8/2026
- Herbalife to Participate in 1 on 1 Meetings at Maxim Growth Summit on October 14Yahoo · 10/5/2026
- Deepa Malik Shares Powerful Lessons on Resilience, Reinvention and Self Belief on Herbalife India's Live Your Best Life, UnscriptedYahoo · 10/1/2026
- Herbalife to Announce Third Quarter 2026 Results on November 2Yahoo · 10/1/2026
- 2 Safe-and-Steady Stocks to Target This Week and 1 We Brush OffYahoo · 9/30/2026
- Herbalife India Joins Hands with Indian Olympic Association as Official Nutrition Partner for the Indian Contingent at Asian Games 2026Yahoo · 9/28/2026
- Should Value Investors Buy Herbalife Ltd (HLF) Stock?Yahoo · 9/24/2026
Insider Activity
Insider Actions →- Frank Lamberti · August 4, 2026 · Tax Withholding1.7K @ $12.8
- Sophie L'Helias · June 4, 2026 · Buy1.2K @ $11.31
- Troy Hicks · May 19, 2026 · Sale10.0K @ $12.32
- Troy Hicks · May 18, 2026 · Option Exercise65.8K @ $9.58
- Troy Hicks · May 18, 2026 · Option Exercise17.5K @ $8.31
- Troy Hicks · May 18, 2026 · Tax Withholding58.1K @ $12.59
- Troy Hicks · May 18, 2026 · Tax Withholding14.6K @ $12.59
- Troy Hicks · May 18, 2026 · Sale38.4K @ $12.93
- Frank Lamberti · May 12, 2026 · Sale135.0K @ $13.5
- Frank Lamberti · May 11, 2026 · Sale7.9K @ $13.86
- Lynda Cloud · May 8, 2026 · Grant11.9K
- Maria Otero · May 8, 2026 · Grant11.9K
- Richard H. Carmona · May 8, 2026 · Grant11.9K
- Michael J. Levitt · May 8, 2026 · Grant11.9K
- Juan Miguel Mendoza · May 8, 2026 · Grant11.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
HLF Featured in Mixed Stock Lists Amid High RSI
Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.
HLF Featured in Mixed Stock Lists Amid High RSI. Recent articles from Yahoo and Benzinga discuss Herbalife in the context of long-term holdings and risk-off strategies, with one piece specifically citing reasons to avoid the stock. These mixed opinions appear while the stock trades near its 52-week high, reflecting a divergence between current price action and some analyst views. The news highlights ongoing debate over the company's value proposition among investors.